Merck KGaA Lowered to Sell at Societe Generale (MKGAY)
Merck KGaA (NASDAQ:MKGAY) was downgraded by analysts at Societe Generale from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, TheFlyOnTheWall.com reports.
Shares of Merck KGaA (NASDAQ:MKGAY) traded down 9.76% during mid-day trading on Monday, hitting $54.55. The stock had a trading volume of 805 shares. Merck KGaA has a one year low of $43.22 and a one year high of $61.72. The stock has a 50-day moving average of $58. and a 200-day moving average of $54.83. The company has a market cap of $35.611 billion and a price-to-earnings ratio of 25.59.
Merck KGaA is operating in the pharmaceutical and chemical business sectors. The Pharmaceuticals business sector comprises innovative prescription drugs as well as over-the-counter products, and operates through three division: Merck Serono, which markets products used in oncology and treatment of autoimmune and inflammatory diseases, among others, Consumer Health Care, which markets products for everyday health protection and mobility, among others and Clinical Trials, engaged in conducting clinical trails.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.